Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology SA

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc.

Celyad Oncology is a biotechnology company that develops technologies for chimeric antigen receptor (CAR) T-cells.

Metric
Company Name	Celyad Oncology SA	Marker Therapeutics, Inc.
Symbol	CYAD	MRKR
MSH ID	COM:CELYAD	COM:MARKERTHERAPEUTICS
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	BE	US
Stage		Grant
Employee Count	17	8
Website	celyad.com	markertherapeutics.com
LinkedIn		marker-therapeutics
Founders

Metric
Market Cap	11.77M	44.42M
Enterprise Value
Monthly Web Traffic		4.75K
Web Traffic Growth		-0.22
Valuation
Raised Capital		2M

Metric
Revenue	107.74K	3.31M
Revenue (LTM)
Revenue (NTM)
Gross Profit	34.86K	3.31M
EBITDA	-11.19M	-14.58M
Operating Income	-11.19M	-14.58M
Net Income	-8.92M	-16.97M
EPS	-0.35	-1.93
Diluted EPS	-0.35	-1.93
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53	0.36
Operating Profit Margin	-103.22	-1.54
EBITDA Margin	-103.89	-4.40
Net Profit Margin	-82.82	-0.88
Return on Equity	5.42	-0.36
Return on Assets	-0.52	-0.40
Return on Capital Employed	-0.75	-0.97

COM:CELYAD

Celyad Oncology

Last Close

0.65

25/11 09:13

Market Cap

11.14M

Beta: -

Volume Today

8.74K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.22	-4.26
P/B Ratio	2.09	2.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	329.55	15.58
EV Multiple	0.12	-2.73

Metric
Days Sales Outstanding		2.88
Days Payables Outstanding		249.06
Days Inventory Outstanding	14.05K	0.00
Operating Cycle	17.39K	243.84
Cash Conversion Cycle	16.02K	243.84
Asset Turnover	0.01	0.54

Metric
Operating Cash Flow	-16.06M	-16.44M
Free Cash Flow	-17.04M	-16.44M
Cash Flow to Debt	-0.91	8.84
Operating Cash Flow/Sales	-134.75	-1.93
Free Cash Flow Yield	-2.65	-0.51

Metric
Cash & Equivalents	7.40M	15.11M
Accounts Receivable		1.37M
Inventory		1
Goodwill
Debt to Capitalization	2.60
Debt to Assets	0.01	-0.12
Current Ratio	1.42	7.01
Quick Ratio	3.79	6.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue		1.60
SG&A to Revenue		0.79